Skip to main content
Top
Published in: Molecular Imaging and Biology 6/2008

01-11-2008 | Research Article

Radiation Dose Estimates for [18F]5-Fluorouracil Derived from PET-Based and Tissue-Based Methods in Rats

Authors: Adam L. Kesner, Wei-Ann Hsueh, Johannes Czernin, Henry Padgett, Michael E. Phelps, Daniel H. S. Silverman

Published in: Molecular Imaging and Biology | Issue 6/2008

Login to get access

Abstract

Introduction

Radiation dosimetry assessment often begins with measuring pharmaceutical biodistribution in rodents. The traditional approach to dosimetry in rodents involves a radioassay ex vivo of harvested organs at different time points following administration of the radiopharmaceutical. The emergence of small-animal positron emission tomography (PET) presents the opportunity for an alternative method for making radiodosimetry estimates previously employed only in humans and large animals. In the current manuscript, normal-tissue absorbed dose estimates for the 18F-labeled chemotherapy agent [18F]5-fluorouracil ([18F]5-FU) were derived by PET imaging- and by tissue harvesting-based methods in rats.

Methods

Small-animal PET data were acquired dynamically for up to 2 h after injection of [18F]5-FU in anesthetized rats (n = 16). Combined polynomial and exponential functions were used to model the harvesting-based and imaging-based time–activity data. The measured time–activity data were extrapolated to modeled (i.e., Standard Man) human organs and human absorbed doses calculated.

Results

Organ activities derived by imaging-based and by harvesting-based methods were highly correlated (r > 0.999) as were the projected human dosimetry estimates across organs (r = 0.998) obtained with each method. The tissues calculated to receive highest radiation dose by both methods were related to routes of excretion (bladder wall, liver, and intestines). The harvesting-based and imaging-based methods yielded effective dose (ED) of 2.94E−2 and 2.97E−2 mSv/MBq, respectively.

Conclusions

Small-animal PET presents an opportunity for providing radiation dose estimates with statistical and logistical advantages over traditional tissue harvesting-based methods.
Literature
1.
go back to reference Tang G, Wang M, Tang X, Luo L, Gan M (2003) Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F]fluoroethyl)-l-tyrosine as oncologic PET tracer. Appl Radiat Isot 58:219–225PubMedCrossRef Tang G, Wang M, Tang X, Luo L, Gan M (2003) Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F]fluoroethyl)-l-tyrosine as oncologic PET tracer. Appl Radiat Isot 58:219–225PubMedCrossRef
2.
go back to reference DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS et al (2001) Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42:1805–1814PubMed DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS et al (2001) Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42:1805–1814PubMed
3.
go back to reference Santens P, De Vos F, Thierens H, Decoo D, Slegers G, Dierckx RA et al (1998) Biodistribution and dosimetry of carbon-11-methoxyprogabidic acid, a possible ligand for GABA-receptors in the brain. J Nucl Med 39:307–310PubMed Santens P, De Vos F, Thierens H, Decoo D, Slegers G, Dierckx RA et al (1998) Biodistribution and dosimetry of carbon-11-methoxyprogabidic acid, a possible ligand for GABA-receptors in the brain. J Nucl Med 39:307–310PubMed
4.
go back to reference DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE (2002) Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 43:92–96PubMed DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE (2002) Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 43:92–96PubMed
5.
go back to reference Deterding TA, Votaw JR, Wang CK, Eshima D, Eshima L, Keil R et al (2001) Biodistribution and radiation dosimetry of the dopamine transporter ligand. J Nucl Med 42:376–381PubMed Deterding TA, Votaw JR, Wang CK, Eshima D, Eshima L, Keil R et al (2001) Biodistribution and radiation dosimetry of the dopamine transporter ligand. J Nucl Med 42:376–381PubMed
6.
go back to reference Kurdziel KA, Kiesewetter DO, Carson RE, Eckelman WC, Herscovitch P (2003) Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. J Nucl Med 44:1330–1339PubMed Kurdziel KA, Kiesewetter DO, Carson RE, Eckelman WC, Herscovitch P (2003) Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. J Nucl Med 44:1330–1339PubMed
7.
go back to reference ICRP Publication 62: Radiological Protection in Biomedical Research. Annals of the ICRP Volume 22/3: International Commission on Radiological Protection; 1993 ICRP Publication 62: Radiological Protection in Biomedical Research. Annals of the ICRP Volume 22/3: International Commission on Radiological Protection; 1993
8.
go back to reference Schmidt D, Langen KJ, Herzog H, Wirths J, Holschbach M, Kiwit JC et al (1997) Whole-body kinetics and dosimetry of L-3-123I-iodo-alpha-methyltyrosine. Eur J Nucl Med 24:1162–1166PubMed Schmidt D, Langen KJ, Herzog H, Wirths J, Holschbach M, Kiwit JC et al (1997) Whole-body kinetics and dosimetry of L-3-123I-iodo-alpha-methyltyrosine. Eur J Nucl Med 24:1162–1166PubMed
9.
go back to reference Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I et al (2002) Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 29:147–157PubMedCrossRef Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I et al (2002) Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 29:147–157PubMedCrossRef
10.
go back to reference Palm S, Enmon RM Jr., Matei C, Kolbert KS, Xu S, Zanzonico PB et al (2003) Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med 44:1148–1155PubMed Palm S, Enmon RM Jr., Matei C, Kolbert KS, Xu S, Zanzonico PB et al (2003) Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med 44:1148–1155PubMed
11.
go back to reference Loevinger R, Budinger T, Watson E (1988) MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, New York, NY Loevinger R, Budinger T, Watson E (1988) MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, New York, NY
12.
go back to reference Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R et al (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179:663–666PubMedCrossRef Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R et al (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179:663–666PubMedCrossRef
13.
go back to reference Shani J, Wolf W (1977) A model for prediction of chemotherapy response to 5-fluorouracil based on the differential distribution of 5-[18F]fluorouracil in sensitive versus resistant lymphocytic leukemia in mice. Cancer Res 37:2306–2308PubMed Shani J, Wolf W (1977) A model for prediction of chemotherapy response to 5-fluorouracil based on the differential distribution of 5-[18F]fluorouracil in sensitive versus resistant lymphocytic leukemia in mice. Cancer Res 37:2306–2308PubMed
14.
go back to reference Bellemann ME, Brix G, Haberkorn U, Ostertag HJ, Lorenz WJ (1994) Drug-specific 19F NMR and dynamic 18F PET imaging of the cytostatic agent 5-fluorouracil. IEEE Trans Nucl Sci 41:2856–2861CrossRef Bellemann ME, Brix G, Haberkorn U, Ostertag HJ, Lorenz WJ (1994) Drug-specific 19F NMR and dynamic 18F PET imaging of the cytostatic agent 5-fluorouracil. IEEE Trans Nucl Sci 41:2856–2861CrossRef
15.
go back to reference Bading JR, Alauddin MM, Fissekis JD, Shahinian AH, Joung J, Spector T et al (2000) Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. J Nucl Med 41:1714–1724PubMed Bading JR, Alauddin MM, Fissekis JD, Shahinian AH, Joung J, Spector T et al (2000) Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. J Nucl Med 41:1714–1724PubMed
16.
go back to reference Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Mohler M, Oberdorfer F et al (1998) Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 39:1197–1202PubMed Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Mohler M, Oberdorfer F et al (1998) Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 39:1197–1202PubMed
17.
go back to reference Cristy M, Eckerman K (1987) Specific absorbed fractions of energy at various ages from internal photons sources. Oak Ridge National Laboratory, Oak Ridge, TN Cristy M, Eckerman K (1987) Specific absorbed fractions of energy at various ages from internal photons sources. Oak Ridge National Laboratory, Oak Ridge, TN
18.
go back to reference Segars WP, Tsui BM, Frey EC, Johnson GA, Berr SS (2004) Development of a 4-D digital mouse phantom for molecular imaging research. Mol Imaging Biol 6:149–159PubMedCrossRef Segars WP, Tsui BM, Frey EC, Johnson GA, Berr SS (2004) Development of a 4-D digital mouse phantom for molecular imaging research. Mol Imaging Biol 6:149–159PubMedCrossRef
19.
go back to reference Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023–1027PubMed Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023–1027PubMed
20.
go back to reference Kirschner A, Ice R, Beierwaltes W (1975) Letters to the editor. J Nucl Med 16:248–249 Kirschner A, Ice R, Beierwaltes W (1975) Letters to the editor. J Nucl Med 16:248–249
21.
go back to reference Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF et al (1999) MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40:37S–61SPubMed Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF et al (1999) MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40:37S–61SPubMed
22.
go back to reference Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA (2003) 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med 44:1482–1488PubMed Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA (2003) 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med 44:1482–1488PubMed
23.
go back to reference Mankoff DA, Peterson LM, Tewson TJ, Link JM, Gralow JR, Graham MM et al (2001) [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 42:679–684PubMed Mankoff DA, Peterson LM, Tewson TJ, Link JM, Gralow JR, Graham MM et al (2001) [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 42:679–684PubMed
24.
go back to reference Bevington P, Robinson D (1992) Data Reduction and Error Analysis for the Physical Sciences, 2nd ed. McGraw-Hill, New York, NY Bevington P, Robinson D (1992) Data Reduction and Error Analysis for the Physical Sciences, 2nd ed. McGraw-Hill, New York, NY
25.
go back to reference ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals. International Commission on Radiological Protection; 1987 ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals. International Commission on Radiological Protection; 1987
26.
go back to reference Brix G, Bellemann ME, Gerlach L, Haberkorn U (1998) Intra- and extracellular fluorouracil uptake: assessment with contrast-enhanced metabolic F-19 MR imaging. Radiology 209:259–267PubMed Brix G, Bellemann ME, Gerlach L, Haberkorn U (1998) Intra- and extracellular fluorouracil uptake: assessment with contrast-enhanced metabolic F-19 MR imaging. Radiology 209:259–267PubMed
27.
go back to reference Brix G, Bellemann ME, Haberkorn U, Gerlach L, Bachert P, Lorenz WJ (1995) Mapping the biodistribution and catabolism of 5-fluorouracil in tumor-bearing rats by chemical-shift selective 19F MR imaging. Magn Reson Med 34:302–307PubMedCrossRef Brix G, Bellemann ME, Haberkorn U, Gerlach L, Bachert P, Lorenz WJ (1995) Mapping the biodistribution and catabolism of 5-fluorouracil in tumor-bearing rats by chemical-shift selective 19F MR imaging. Magn Reson Med 34:302–307PubMedCrossRef
28.
go back to reference Kissel J, Brix G, Bellemann ME, Strauss LG, Dimitrakopoulou-Strauss A, Port R et al (1997) Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 57:3415–3423PubMed Kissel J, Brix G, Bellemann ME, Strauss LG, Dimitrakopoulou-Strauss A, Port R et al (1997) Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 57:3415–3423PubMed
29.
go back to reference Visser GW, Gorree GC, Peters GJ, Herscheid JD (1990) Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose. Cancer Chemother Pharmacol 26:205–209PubMedCrossRef Visser GW, Gorree GC, Peters GJ, Herscheid JD (1990) Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose. Cancer Chemother Pharmacol 26:205–209PubMedCrossRef
30.
go back to reference Shani J, Young D, Schlesinger T, Siemsen JK, Chlebowski RT, Bateman JR et al (1982) Dosimetry and preliminary human studies of 18F-5-fluorouracil. Int J Nucl Med Biol 9:25–35PubMedCrossRef Shani J, Young D, Schlesinger T, Siemsen JK, Chlebowski RT, Bateman JR et al (1982) Dosimetry and preliminary human studies of 18F-5-fluorouracil. Int J Nucl Med Biol 9:25–35PubMedCrossRef
31.
go back to reference Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J et al (2006) Predicting chemotherapy response to paclitaxel with 18F-fluoropaclitaxel and PET. J Nucl Med 47:1995–1999PubMed Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J et al (2006) Predicting chemotherapy response to paclitaxel with 18F-fluoropaclitaxel and PET. J Nucl Med 47:1995–1999PubMed
32.
go back to reference Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD et al (2005) Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med 46:1866–1871PubMed Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD et al (2005) Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med 46:1866–1871PubMed
33.
go back to reference Kesner AL, Hsueh W-A, Htet NL, Pio BS, Czernin J, Pegram MD, Phelps ME, Silverman DHS (2007) Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts. J Nucl Med 48:2021–2027; First published on November 15, 2007 Kesner AL, Hsueh W-A, Htet NL, Pio BS, Czernin J, Pegram MD, Phelps ME, Silverman DHS (2007) Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts. J Nucl Med 48:2021–2027; First published on November 15, 2007
Metadata
Title
Radiation Dose Estimates for [18F]5-Fluorouracil Derived from PET-Based and Tissue-Based Methods in Rats
Authors
Adam L. Kesner
Wei-Ann Hsueh
Johannes Czernin
Henry Padgett
Michael E. Phelps
Daniel H. S. Silverman
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 6/2008
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-008-0160-5

Other articles of this Issue 6/2008

Molecular Imaging and Biology 6/2008 Go to the issue